Pharmaceutical Executive Digest Europe - February 25, 2009 - (Page 8) Critical Vision unintended. It is that it offers the opportunity for an experiment to help anyone, like myself, who is bemused by what people will pay for pharma companies. This hopelessly uncontrolled experiment effectively pits Pfizer’s spending strategy against GSK’s more painstaking approach. Its random nature comes from the fact that at roughly the time Pfizer chooses to spend $68 billion on Wyeth, GSK had spent precisely one-tenth of that, $6.8 billion, on in-licensing products and platform technologies (see Table 1). developing them. It is harder to turn an enormous company around than to make it even more enormous. New times also require new strategies. The mega-merger is not only not new, it brings with it a dire track-record in terms of shareholder value. So I will be watching this basket of products as closely as everyone else follows the progress of Pfizer–Wyeth. But not nearly as closely as I watch the prices of other houses I could be buying. For news on GSK’s recent price-cutting announcement, click here. MISS IT, MISS OUT! Ensure you receive Pharm Exec Europe every week. Click here to subscribe for FREE now! The mega-merger is not only not new, it brings with it a dire trackrecord in terms of shareholder value. Theoretically, it is therefore possible to track the performance of these two investments one or five years down the road to see which has contributed most to the bottom line. My money would go on the UK company, not only because it was streets ahead of any other top ten player in terms of the number of deals struck for new therapies and their value but, more importantly, because it requires more effort in areas that matter, such as evaluating products and the people pharmexec.com 1 9 NEWS BIOFUTURES 2 11 FROM THE EDITOR / NEWS DIGITAL MARKETING 6 CALENDAR 7 JACKY LAW 13 ON THE MOVE SUBSCRIBE TO PHARM EXEC http://www.pharmexeceurope.com/europharmexec/News/GSK-to-cut-prices-for-poorest-countries/ArticleStandard/Article/detail/581654?contextCategoryId=3062 http://www.pharmexeceurope.com/europharmexec/newsletter/subscribeNewsletter.jsp http://www.pharmexeceurope.com/europharmexec/newsletter/subscribeNewsletter.jsp
Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Digest Europe - February 25, 2009 Pharmaceutical Executive Digest Europe - February 25, 2009 Contents From the Editor News Calendar Critical Vision Biofutures Digital Marketing On the Move Pharmaceutical Executive Digest Europe - February 25, 2009 Pharmaceutical Executive Digest Europe - February 25, 2009 - Contents (Page 1) Pharmaceutical Executive Digest Europe - February 25, 2009 - News (Page 2) Pharmaceutical Executive Digest Europe - February 25, 2009 - News (Page 3) Pharmaceutical Executive Digest Europe - February 25, 2009 - News (Page 4) Pharmaceutical Executive Digest Europe - February 25, 2009 - News (Page 5) Pharmaceutical Executive Digest Europe - February 25, 2009 - Calendar (Page 6) Pharmaceutical Executive Digest Europe - February 25, 2009 - Critical Vision (Page 7) Pharmaceutical Executive Digest Europe - February 25, 2009 - Critical Vision (Page 8) Pharmaceutical Executive Digest Europe - February 25, 2009 - Biofutures (Page 9) Pharmaceutical Executive Digest Europe - February 25, 2009 - Biofutures (Page 10) Pharmaceutical Executive Digest Europe - February 25, 2009 - Digital Marketing (Page 11) Pharmaceutical Executive Digest Europe - February 25, 2009 - Digital Marketing (Page 12) Pharmaceutical Executive Digest Europe - February 25, 2009 - On the Move (Page 13)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.